Incannex Healthcare

Contributing Author

Recent Articles by Incannex Healthcare

Jun-24	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch IXHL GlobeNewswire
Jun-18	Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X IXHL GlobeNewswire
Jun-17	Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy IXHL GlobeNewswire
Jun-12	Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution IXHL GlobeNewswire
Jun-03	Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program IXHL GlobeNewswire
May-29	Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance IXHL GlobeNewswire
May-28	Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results IXHL GlobeNewswire
May-20	Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution IXHL GlobeNewswire
May-16	Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants IXHL GlobeNewswire
May-15	Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates IXHL GlobeNewswire
May-14	Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) IXHL GlobeNewswire